TABLE 2.

Percentages of S. aureusisolates susceptible to nonglycopeptide antimicrobial agents at different vancomycin MICs

Antimicrobial agent% of MSSA isolates with vancomycin MIC (μg/ml) of:% of MRSA isolates with vancomycin MIC (μg/ml) of:
≤0.5 (n = 2,702)1 (n = 1,219)≥2 (n = 11)≤0.5 (n = 921)1 (n = 1,138)≥2 (n = 12)
Ciprofloxacin95.193.0a72.76.65.48.3
Clindamycin96.089.7a72.748.338.7a25.0
Doxycycline99.999.990.999.698.3a91.7
Erythromycin76.573.445.55.73.3a8.3
Gentamicin99.198.881.885.582.275.0
Rifampin99.799.2100.098.195.0a100.0
TMP/SMXb98.096.3a90.995.693.891.7
  • a Statistical difference compared to S. aureus with vancomycin MIC of ≤0.5 μg/ml (P < 0.05).

  • b TMP/SMX, trimethoprim-sulfamethoxazole.